Vaxcyte (NASDAQ:PCVX) Receives Buy Rating from Guggenheim

Guggenheim reissued their buy rating on shares of Vaxcyte (NASDAQ:PCVX) in a research report released on Wednesday,Benzinga reports. They currently have a $160.00 price target on the stock.

Other equities research analysts also recently issued reports about the stock. Needham & Company LLC reiterated a “buy” rating and set a $140.00 price target on shares of Vaxcyte in a research report on Wednesday, February 26th. The Goldman Sachs Group began coverage on shares of Vaxcyte in a research report on Friday, December 20th. They set a “buy” rating and a $135.00 price target for the company. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $147.50.

Vaxcyte Trading Up 4.9 %

Shares of PCVX opened at $73.24 on Wednesday. Vaxcyte has a twelve month low of $58.10 and a twelve month high of $121.06. The stock’s 50 day moving average is $82.65 and its two-hundred day moving average is $94.44. The firm has a market capitalization of $9.43 billion, a PE ratio of -15.92 and a beta of 1.02.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($1.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.14. On average, sell-side analysts predict that Vaxcyte will post -4.21 EPS for the current year.

Insider Buying and Selling

In other Vaxcyte news, Director Teri Loxam sold 6,250 shares of Vaxcyte stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $85.11, for a total value of $531,937.50. Following the completion of the sale, the director now directly owns 7,175 shares of the company’s stock, valued at approximately $610,664.25. The trade was a 46.55 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Andrew Guggenhime sold 8,000 shares of Vaxcyte stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $88.78, for a total transaction of $710,240.00. Following the completion of the sale, the chief financial officer now directly owns 109,491 shares of the company’s stock, valued at $9,720,610.98. The trade was a 6.81 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 54,250 shares of company stock worth $4,550,258 in the last ninety days. Insiders own 3.10% of the company’s stock.

Institutional Trading of Vaxcyte

Several hedge funds and other institutional investors have recently bought and sold shares of PCVX. Whipplewood Advisors LLC purchased a new stake in Vaxcyte in the 4th quarter worth approximately $28,000. Smartleaf Asset Management LLC grew its stake in shares of Vaxcyte by 188.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 398 shares of the company’s stock valued at $33,000 after buying an additional 260 shares during the period. National Bank of Canada FI purchased a new stake in shares of Vaxcyte during the 4th quarter valued at $41,000. Blue Trust Inc. grew its stake in shares of Vaxcyte by 100.0% during the 4th quarter. Blue Trust Inc. now owns 742 shares of the company’s stock valued at $61,000 after buying an additional 371 shares during the period. Finally, Assetmark Inc. grew its stake in shares of Vaxcyte by 77,500.0% during the 4th quarter. Assetmark Inc. now owns 776 shares of the company’s stock valued at $64,000 after buying an additional 775 shares during the period. 96.78% of the stock is owned by hedge funds and other institutional investors.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.